Tinzaparin

Generic Name: Tinzaparin

Brand Names: Innohep

Drug Type: Small Molecule

CAS Number: 9041-08-1

Unique Ingredient Identifier: 7UQ7X4Y489

Background: Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Indication: Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.

Associated Conditions: Clotting, Deep Vein Thrombosis, Pulmonary embolism, Deep vein thrombosis, Venous Thromboembolism

Clinical Trials

Thromboprophylaxis in Lower Limb Immobilisation

Phase 3

Recruiting

Conditions: Injury Leg
Thrombosis

Interventions: Drug: Enoxaparin Injectable Solution
Drug: Rivaroxaban
Drug: Tinzaparin Injectable Solution
Drug: Apixaban
Drug: Dalteparin Injectable Solution
Drug: Fondaparinux Injectable Product

First Posted Date: 2024-04-17

Last Posted Date: 2024-11-29

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 10044

Registration Number: NCT06370273

Locations: 🇬🇧
Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, United Kingdom
🇬🇧
Barts Health NHS Trust, London, United Kingdom
🇬🇧
Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom

Study of Low Molecular Weight Heparins

Phase 4

Recruiting

Conditions: Prophylaxis
Venous Thromboembolism
Anticoagulant
Treatment

Interventions: Drug: Dalteparin Prefilled Syringe
Drug: Tinzaparin profiled syringe

First Posted Date: 2023-08-31

Last Posted Date: 2023-08-31

Lead Sponsor: Herlev Hospital

Target Recruit Count: 65000

Registration Number: NCT06020560

Locations: 🇩🇰
Herlev and Gentofte Hospital, Herlev, Denmark
🇩🇰
Nykøbing Falster Hospital, Nykøbing Falster, Denmark
🇩🇰
Rigshospitalet, Copenhagen, Denmark

and more 6 locations

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Phase 4

Recruiting

Conditions: Venous Thromboembolism
Varicose Veins

Interventions: Drug: Dalteparin Sodium
Drug: Tinzaparin Sodium
Drug: Enoxaparin Sodium
Drug: Rivaroxaban
Drug: Apixaban
Drug: Dabigatran Etexilate

First Posted Date: 2023-02-21

Last Posted Date: 2025-05-02

Lead Sponsor: Imperial College London

Target Recruit Count: 6660

Registration Number: NCT05735639

Locations: 🇬🇧
Imperial College Hospital NHS Foundation Trust, London, United Kingdom

TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Phase 3

Recruiting

Conditions: Thromboembolism
Colorectal Cancer Metastatic

Interventions: Drug: Tinzaparin

First Posted Date: 2022-11-23

Last Posted Date: 2024-05-01

Lead Sponsor: Galician Research Group on Digestive Tumors

Target Recruit Count: 526

Registration Number: NCT05625932

Locations: 🇪🇸
Hospital Universitario De Móstoles, Móstoles, Madrid, Spain
🇪🇸
Hospital Universitario Son Espases, Palma De Mallorca, Baleares, Spain
🇪🇸
Hospital Universitario Príncipe de Asturias (HUPA) de Alcalá de Henares, Alcalá De Henares, Madrid, Spain

and more 32 locations

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Phase 2

Recruiting

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Tinzaparin Injectable Solution

First Posted Date: 2022-03-17

Last Posted Date: 2025-02-27

Lead Sponsor: University Hospital, Linkoeping

Target Recruit Count: 40

Registration Number: NCT05284552

Locations: 🇸🇪
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
🇸🇪
Department of Obstetrics and Gynecology, Highland Hospital, Eksjö, Sweden
🇸🇪
Department of Oncology, Linköping University Hospital, Linköping, Sweden

and more 5 locations

The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer

Phase 3

Recruiting

Conditions: Pancreatic Cancer
Thromboembolism

Interventions: Drug: Innohep

First Posted Date: 2022-01-05

Last Posted Date: 2022-03-29

Lead Sponsor: Michalis Karamouzis

Target Recruit Count: 450

Registration Number: NCT05178628

Locations: 🇬🇷
Institute of Molecular Medicine and Biomedical Research, Athens, Attiki, Greece
🇬🇷
Eygenideio Hospital, Oncology Department, Athens, Attiki, Greece

Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

Conditions: Hospitalization
Covid19

Interventions: Drug: tinzaparin

First Posted Date: 2021-09-08

Last Posted Date: 2021-09-08

Lead Sponsor: University Hospital of Patras

Target Recruit Count: 300

Registration Number: NCT05036824

Locations: 🇬🇷
University General Hospital of Ioannina, Ioannina, Epirus, Greece
🇬🇷
General Hospital of Kerkira "Ag. Irini", Korfu, Ionian Islands, Greece
🇬🇷
Evangelismos General Hospital, Athens, Attica, Greece

and more 4 locations

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Phase 4

Terminated

Conditions: Deep Vein Thrombosis
Post Thrombotic Syndrome

Interventions: Drug: Rivaroxaban
Drug: tinzaparin

First Posted Date: 2021-03-12

Last Posted Date: 2024-04-04

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 9

Registration Number: NCT04794569

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦
Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada

and more 2 locations

Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Not Applicable

Completed

Conditions: Deep Vein Thrombosis
Inflammatory Response

First Posted Date: 2021-02-05

Last Posted Date: 2025-04-02

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Target Recruit Count: 9

Registration Number: NCT04741464

Locations: 🇫🇷
CHU Amiens, Amiens, France

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

Not Applicable

Completed

Conditions: Covid19
Thrombosis

Interventions: Drug: Tinzaparin

First Posted Date: 2021-01-29

Last Posted Date: 2022-09-15

Lead Sponsor: Hospital Universitario Infanta Leonor

Target Recruit Count: 311

Registration Number: NCT04730856

Locations: 🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸
Hospital Virgen de la Luz, Cuenca, Spain
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy